Olivier Taelman: So, Suraj, the short answer is, no. When we look at the DREAM study design, this is not part of the study design. So, that being said, of course, we will further analyze the data and we will also report the regular earnings. And then if I understand the question also correct, I think, what you are referring to is the fact that when surgeons starts during the first implants, they are going through a learning curve and once day reach, we saw already in commercial patients and also in previous study patients that after four implants that they really pass the learning curve and that the placement and also the speed of the implant is only increasing. So repeating a little bit of somehow , no, it’s not part of the study design, but we will definitely take the learnings and also incorporate them going forward and we see that the surgeons only get better after they pass the learning curve of 34 in that.
Suraj Kalia: Fair enough. Olivier, in terms of compliance i.e. they have turned on the Genio and all, how is that being maintained in DREAM, because again, Inspire is an internal pacemaker, right, and you guys are not. So I am just curious if that is a variable that we need to be cognizant of in the final data analysis?
Olivier Taelman: Yeah. Suraj, as you can understand, I cannot comment on compliance in the DREAM trial. But based on historical clinical and commercial compliance data, we know that we are reaching a 91% reporting and compliance reporting using the Genio system more than five days a week and minimum 5 hours a night.
Suraj Kalia: Got it. In Germany, Olivier — and I will keep this as the last question. In Germany, on an apples-to-apples basis, for the same site, it may be somewhat unfair, forgive me, Olivier, I know it’s early in the game. But, let’s say, Suraj walks in into tubing in hospital, right, and he needs hypoglossal nerve stim. How has the decision matrix made between, let’s say, Inspire versus Genio, all things — all other things remaining equal? Thank you for taking my questions.
Olivier Taelman: Yeah. And it’s a very interesting question, Suraj, that you are asking. So what we learned and what we notice this that the influence of the voice of the patient is really important in the selection of the technology that they will get. And also, therefore, we are really increasing our efforts in DTC, we are increasing the effort that we are doing in having a patient health line, and of course, we are also increasing our efforts in interacting not only with ENT surgeons that are doing the implant, but also with SLEEP physicians. So if you would enter the hospital, I am sure that, first of all, the surgeon would inform you what is available and there are two systems at this moment. And then second, I also — I am sure that you as a patient would also have a clear say in the selection of which technology you will go.
And that’s one of the reasons where we feel very confident, because if you explain the position of system has been the single incision, fast procedure, always benefiting from the latest and greatest technology update, I think, not having to undergo a DISE, so let’s not forget. In Germany, we have the label in Germany and Europe. We have the label expansion. The path to getting a treatment solution of hypoglossal nerve stim is much faster if you choose Genio than if the surgeon of the patient would go for the competitors.
Suraj Kalia: Got it. Thank you.
Operator: Thank you. I am showing no further questions at this time. I’d like to turn the call back over to Olivier Taelman, Chief Executive Officer, for any closing remarks.